Dashboard
Manage Tickers

MDGL


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-madrigal-pharmaceuticals-raises-price-target-to-568
HC Wainwright & Co. Maintains Buy on Madri...
11/11/2025 16:21:37

HC Wainwright & Co. analyst Andrew S. Fein maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the pr...

madrigal-pharma-presents-2-yr-data-from-open-label-compensated-mash-cirrhosis-arm-of-phase-3-maestro-nafld-1-trial-at-aasld-2025
Madrigal Pharma Presents 2-Yr Data From Op...
11/10/2025 13:02:39

Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal ...

expedia-sandisk-and-penumbra-are-among-the-top-10-large-cap-gainers-last-week-nov-3-nov-7-are-the-others-in-your-portfolio
Expedia, Sandisk and Penumbra Are Among th...
11/09/2025 12:08:44

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad do...

cantor-fitzgerald-upgrades-madrigal-pharmaceuticals-to-overweight
Cantor Fitzgerald Upgrades Madrigal Pharma...
11/05/2025 13:19:29

Cantor Fitzgerald analyst Prakhar Agrawal upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Neutral to Overweight.

citizens-maintains-market-outperform-on-madrigal-pharmaceuticals-raises-price-target-to-527
Citizens Maintains Market Outperform on Ma...
11/05/2025 13:03:40

Citizens analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and raises the ...

madrigal-pharmaceuticals-q3-eps-508-misses-216-estimate-sales-287268m-beat-245386m-estimate
Madrigal Pharmaceuticals Q3 EPS $(5.08) Mi...
11/04/2025 12:01:12

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(5.08) per share which missed the analyst consensus estima...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

a-look-ahead-madrigal-pharmaceuticalss-earnings-forecast
A Look Ahead: Madrigal Pharmaceuticals's E...
11/03/2025 17:02:23

b-of-a-securities-upgrades-madrigal-pharmaceuticals-to-neutral-raises-price-target-to-445
B of A Securities Upgrades Madrigal Pharma...
11/03/2025 12:06:07

B of A Securities analyst Alexandria Hammond upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Underperform to Neutral an...

madrigal-pharmaceuticals-announces-multiple-mash-and-rezdiffra-data-presentations-at-the-aaslds-the-liver-meeting-nov-711-2025
Madrigal Pharmaceuticals Announces Multipl...
10/28/2025 12:13:12

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis ...

beyond-the-numbers-10-analysts-discuss-madrigal-pharmaceuticals-stock
Beyond The Numbers: 10 Analysts Discuss Ma...
10/15/2025 14:01:11

piper-sandler-maintains-overweight-on-madrigal-pharmaceuticals-raises-price-target-to-540
Piper Sandler Maintains Overweight on Madr...
10/15/2025 13:59:42

Piper Sandler analyst Yasmeen Rahimi maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and raises the price...

truist-securities-initiates-coverage-on-madrigal-pharmaceuticals-with-buy-rating-announces-price-target-of-580
Truist Securities Initiates Coverage On Ma...
10/15/2025 11:35:28

Truist Securities analyst Srikripa Devarakonda initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy ratin...

oppenheimer-maintains-outperform-on-madrigal-pharmaceuticals-raises-price-target-to-590
Oppenheimer Maintains Outperform on Madrig...
10/10/2025 17:51:53

Oppenheimer analyst Jay Olson maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and raises the price target...

6-stocks-goldman-sachs-says-are-poised-for-potential-acquisition-in-next-12-months--including-a-huge-200-winner
6 Stocks Goldman Sachs Says Are Poised For...
09/30/2025 13:11:43

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

a-glimpse-into-the-expert-outlook-on-madrigal-pharmaceuticals-through-7-analysts
A Glimpse Into The Expert Outlook On Madri...
09/29/2025 21:01:08

In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and...

b-riley-securities-maintains-buy-on-madrigal-pharmaceuticals-raises-price-target-to-560
B. Riley Securities Maintains Buy on Madri...
09/29/2025 14:35:05

B. Riley Securities analyst Mayank Mamtani maintains Madrigal Pharmaceuticals (NASDAQ: MDGL) with a Buy and raises the price...

general-motors-to-rally-more-than-24-here-are-10-top-analyst-forecasts-for-friday
General Motors To Rally More Than 24%? Her...
09/12/2025 13:29:52

a-glimpse-into-the-expert-outlook-on-madrigal-pharmaceuticals-through-6-analysts
A Glimpse Into The Expert Outlook On Madri...
09/12/2025 13:01:34

canaccord-genuity-maintains-buy-on-madrigal-pharmaceuticals-raises-price-target-to-526
Canaccord Genuity Maintains Buy on Madriga...
09/12/2025 12:56:28

Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price targe...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION